Investigational drug · Phase 3
buntanetap
Also called: posiphen
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Early Alzheimers Disease, Alzheimer's Dementia (AD), Parkinson's Disease (PD).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "buntanetap"
First trial start
2025
Feb 4, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "buntanetap", any sponsor or status.
Conditions studied
As listed on its trial records.
- Early Alzheimers Disease
- Alzheimer's Dementia (AD)
- Parkinson's Disease (PD)
- Deep Brain Stimulation
Approved drugs for the same conditions: Alzheimer's disease · Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "buntanetap" as an intervention, largest first.
- A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early ADPivotal-lookingActive, not recruiting
Annovis Bio Inc.Industry
NCT06709014 · 861 participants · Start Feb 4, 2025 · Primary completion Dec 2027
Drug: buntanetap/posiphen; Placebo · For: Early Alzheimers Disease
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 78 sites in all
- A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PDPivotal-lookingCompleted
Annovis Bio Inc.Industry
NCT05357989 · 523 participants · Start Aug 3, 2022 · Primary completion Dec 4, 2023
Drug: buntanetap/posiphen; Placebo · For: Parkinson's Disease, Idiopathic
Sites: Birmingham, Alabama; Sun City, Arizona; Fountain Valley, California · 69 sites in all
- A Study of Buntanetap in Participants With PDPivotal-lookingRecruiting
Annovis Bio Inc.Industry
NCT07284784 · 500 participants (planned) · Start Jan 9, 2026 · Primary completion Sep 2029
Drug: buntanetap/posiphen · For: Parkinson's Disease (PD); Deep Brain Stimulation
Sites: Birmingham, Alabama; Sun City, Arizona; Fountain Valley, California · 29 sites in all
- An Open-label Long-term Safety Study of Buntanetap in Participants With ADPivotal-lookingNot yet recruiting
Annovis Bio Inc.Industry
NCT07757204 · 400 participants (planned) · Start Nov 21, 2026 · Primary completion Feb 21, 2030
Drug: buntanetap/posiphen · For: Alzheimer's Dementia (AD)
Sites: Englewood, Colorado; Daytona Beach, Florida; Maitland, Florida · 14 sites in all
- A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate ADPivotal-lookingCompleted
Annovis Bio Inc.Industry
NCT05686044 · 351 participants · Start Apr 1, 2023 · Primary completion Feb 13, 2024
Drug: Buntanetap/Posiphen; Placebo · For: Alzheimer Disease
Sites: Gilbert, Arizona; Phoenix, Arizona; Fort Smith, Arkansas · 54 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Current Possible Newer Pharmacological Treatment Options for Alzheimer's Disease.
Miziak B, Pluta R, Czuczwar SJ · Int J Mol Sci 2026
- Combined administration of buntanetap and dulaglutide counteracts synaptic dysfunction and memory loss in an Alzheimer's disease mouse model.
Acquarone E, Gutierrez SBG, Zhang H, et al. · Alzheimers Dement (N Y) 2026
- Analysis of the Efficacy of Acetylcholinesterase Inhibitors in the Treatment of Alzheimer's Disease, Literature Review.
Petrov W, Ślebioda D, Koziska R, et al. · Int J Mol Sci 2026
- A Conjugate of Aminoadamantane and Tetrahydro-γ-Carboline Inhibits Accumulation of Mutant α-Synuclein A53T in the Cellular Model of Proteinopathy.
Burak MV, Pukaeva NE, Kryshkova VS, et al. · Biochemistry (Mosc) 2026
- Pharmacokinetics of Novel Crystalline Buntanetap in Mice, Dogs, and Humans.
Morin A, Christie M, Damiano E, et al. · Biomolecules 2025
- Gastroretentive Delivery Approach to Address pH-Dependent Degradation of (+)- and (-)-Phenserine.
Verma P, Rezaei L, Govindarajan R, et al. · AAPS PharmSciTech 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.